Credits: Canva
The winter season compels us to sit at one place, under the blanket, at the ease of warmth. But aren't we all aware of the dangers of a sedentary lifestyle? And when it is winter, it makes it more so stagnant. Not just that, but now a new study from the University of Iowa says that being a couch potato could lead to 19 chronic conditions. Among the 19 chronic conditions, obesity, diabetes, depression and heart diseases also made it to the list.
Research shows that among many diseases, increased blood pressure, high blood sugar, excess body fat around the waist, unhealthy cholesterol levels that leads to metabolic syndrome, cardiovascular disease and cancer are also there. This is why any extended sitting whether at desk, behind the wheel or the screen can be harmful.
The team of researchers from various departments at the University of Iowa conducted a detailed study where they analyzed records from over 40,000 patients at a major Midwestern hospital system. In the records, they looked at the extensive physical inactivity of these patients and how it impacted their overall health.
The study and the detailed analysis is published in the journal Preventing Chronic Disease and studies.
As part of conducting the study, a 30-second exercise survey was conducted. Then, patients were also asked two questions: how many days per week they engaged in moderate to vigorous exercise and for how many minutes per session? On the basis of response, the patients were categorized into three groups:
As per Lucas Carr, associate professor in the Department of Health and Human Physiology and study's corresponding author, "This two-question survey typically takes fewer than 30 seconds for a patient to complete so it does not interfere with their visit. But it can tell us a whole lot about that patient's overall health."
The study got 7,261 responses, and it found that around 60% of them met the recommended guidelines for exercising. These people met the 150 minutes or more minutes of moderate exercise per week. However, almost 36% exercised less than 150 minutes per week and 4% reported no physical activity.
The study also found that people experienced lower rates of depression. 15% of people who exercise for 150 minutes or more, or at least for some amount of time could experience depression, as compared to 26% of those who are inactive. Similarly, for obesity, the numbers are 12% versus 21% for obesity, 20% versus 35% for hypertension and the similar trend was seen in other diseases, and markers of good health, including lower resting pulse rates, and cholesterol profiles.
Patients with no physical activity carried a median of 2.16 chronic conditions, this number was 1.49 conditions in insufficiently active patients and dropped to 1.17 in active patients.
Credit: Instagram/Canva
Harry Potter star Daniel Radcliffe has quit smoking after 20 long years. The reason: his two–year–old son with girlfriend Erin Darke.
Speaking to media outlet Vulture, the 36-year-old English actor shared that after becoming a father, he was inspired by intrusive thoughts about his mortality, which enabled him to quit the deadly habit after two decades.
"I smoked for 20 years pretty heavily, and I was never even thinking about quitting, and then shortly after having my son, the intrusive thoughts of my own death really helped as an incentive to quit," Radcliffe was quoted as saying.
Radcliffe also shared how a book -- The Easy Way to Quit Smoking, by Alan Carr -- helped him decide to quit smoking.
"It may not work for everybody, but it really worked for me," noted the star, currently starring in the Broadway play Every Brilliant Thing.
Earlier this month, the actor spoke with WSJ Magazine and shared that from being on “cigarettes all day”, he's transformed into a fitness freak.
Smoking can affect all organs in our body. While lung cancer and tuberculosis are the most prominent ones, smoking can seriously increase the risk of several chronic diseases. These include:
While quitting tobacco is important, it is a difficult task, with some people finding it harder to quit than others. It may be important to seek help quitting.
Also read: Cigarettes And The Female Body: The Hormonal Toll We Don’t Talk About
These strategies have shown varying levels of success in aiding smokers to quit permanently. In addition, alternative methods like e-cigarettes and mindfulness-based techniques have gained traction in helping reduce smoking addiction.
Behavioral Support
Quitting smoking isn’t just about resisting cravings. Often, behavioral support through counseling or therapy is crucial for tackling the psychological aspects of addiction. Behavioral therapy involves working with a trained professional to identify triggers, develop coping strategies, and create a tailored quit plan. Research shows that combining counseling with other quit methods can significantly increase success rates.
Prescription Medications
Some medications, such as varenicline (Chantix) and bupropion (Zyban), have been shown to help people quit smoking by reducing cravings and withdrawal symptoms. Experts suggest that varenicline works by blocking the effects of nicotine in the brain, while bupropion is an antidepressant that helps manage withdrawal symptoms. Both medications are generally more effective when combined with behavioral therapy.
Nicotine Replacement Therapy (NRT)
Nicotine replacement products, such as nicotine patches, gums, lozenges, and nasal sprays, deliver controlled amounts of nicotine to ease withdrawal symptoms. According to experts at Harvard Health, NRT can double the chances of quitting by alleviating physical cravings while the person works on overcoming the psychological addiction.
Credit: Canva
About 10.6 percent –15 percent of India's population suffers from some form of mental health conditions, with 15 percent of the adult population also requiring active intervention.
To enable researchers to gather as well as systematically document data on patients with major forms of mental illness, neuroscientists in India have developed CALM-Brain — a digital repository of data on brain structure and function from a range of psychiatric disorders.
CALM-Brain contains data from over 2,000 participants from 900 families across the country.
CALM-Brain will help clinicians and researchers
“CALM-Brain was conceived as a method to assemble data from multiple scales of analysis of brain structure and function on a single platform. We believe that the application of modern methods of data analysis to this dataset will help bridge the gap between these scales of analysis,” said Prof. Raghu Padinjat, CBM co-ordinator at CBM-NCBS, in a statement.
Also read: World Happiness Report 2026 Flags Social Media Harms On Adolescents' Mental Well-being
CALM-Brain is the result of collaborative efforts of researchers at the Rohini Nilekani Centre for Brain and Mind (CBM) — a partnership between the National Institute of Mental Health and Neuro Sciences (NIMHANS) and the National Centre for Biological Sciences (NCBS) - TIFR.
CALM-Brain is India’s first-of-its-kind repository of clinical, neuroimaging, behavioral, genetic, and other datasets on disorders such as:
The dataset is also linked to a biorepository of stem cells, which can be used to perform biological research in psychiatry to understand the origins of such severe mental illnesses.
“The primary goals of the project are to identify biological markers of severe psychiatric illnesses, which cut across traditional diagnostic frameworks. In addition, we will try to identify fundamental biological mechanisms of the disease and medication response,” said Prof. Y.C. Janardhan Reddy, CBM coordinator at CBM-NIMHANS.
Mental wellness is a major health and economic concern in India. The World Health Organization (WHO) estimates India’s economic loss due to mental health conditions to be USD 1.03 trillion (2012-2030).
Recently, health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.
"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.
They added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)" among citizens.
To address the rising burden, the government aims to launch NIMHANS-2 — first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27 — to deliver specialized care for mental health and neurological disorders in north India.
"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," FM Sitharaman said.
Credit: iStock
Metformin has remained the safe and most effective first-line treatment for Type 2 diabetes for the last 60 years. The anti-diabetic drug has been known to work through the liver and gut to lower blood sugar levels and improve the way the body handles insulin.
However, a new study has, for the first time, shown that metformin probably works through the brain, and neurons in a specific region boost its anti-diabetic effects.
The findings open up potential for more targeted and effective diabetes therapies as well as for improving brain health.
The international team of researchers led by those at Baylor College of Medicine, in the US, decoded a brain-based pathway involved in metformin's ability to lower blood sugar.
They found that the widely used diabetes medication switches off a key protein and activates specific neurons, and lowers blood sugar through a previously hidden pathway.
"Metformin is not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels," said corresponding author Dr. Makoto Fukuda, associate professor of pediatrics - nutrition at Baylor.
The new study, published in Science Advances, targeted a small protein called Rap1 -- located in a brain region known as the ventromedial hypothalamus (VMH).
Mice studies proved that metformin fights blood sugar by suppressing the activity of Rap1 in VMH.
To prove the findings, the team deployed genetically engineered mice without Rap1 in the brain.
In mice with a high-fat diet that models type 2 diabetes, low doses of metformin did not improve their blood sugar levels.
On the contrary, when metformin was delivered in very small amounts directly into the brains of diabetic mice, it effectively lowered blood sugar levels.
Further, the team found that SF1 neurons located in the VMH are helping metformin to fight diabetes.
When the team measured the electrical activity of these neurons, they found that metformin’s activity increased only when Rap1 was present
The findings demonstrated that Rap1 is required for metformin to activate these brain cells and regulate blood sugar.
"This discovery changes how we think about metformin," Dr. Fukuda said.
Also read: Indian Drug Regulator Flagged 90 Combination Medicines Sold Without Approval
Metformin has also shown potential to boost fertility levels in people with polycystic ovary syndrome (PCOS) -- a condition that affects how the ovaries work.
Metformin treats PCOS by lowering insulin and blood sugar levels. This can also improve ovulation and encourage regular periods.
Metformin has previously shown its potential for slowing brain aging and improve lifespan.
While metformin is safe for most adults and children aged 10 years and older, the drug may not suitable for some people. this includes people who:
© 2024 Bennett, Coleman & Company Limited